Tomáš Páleníček
Psychopharmacologist and Clinical Researcher
Data updated
Research Footprint
Tomáš Páleníček appears in 20 tracked papers (2012–2026), most studied alongside Psilocybin, Placebo and 5-MeO-DMT, across Depressive Disorders, Neuroimaging & Brain Measures and Healthy Volunteers.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: František Tylš, Martin Brunovský and Michal Kuchar.
Publication Landscape
How the 20 papers Blossom tracks for Tomáš Páleníček line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Tomáš Páleníček's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 20 of 20 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Tomáš Páleníček publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Tomáš Páleníček publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Tomáš Páleníček is a Czech clinical neuroscientist and psychopharmacologist whose work spans preclinical and human experimental studies of serotonergic psychedelics. He has contributed to both animal and human research programmes examining the neurophysiological and behavioural effects of compounds such as psilocin/psilocybin and 5‑MeO‑DMT. His research portfolio includes cross‑species investigations of perceptual distortions, EEG and event‑related potential studies (P300, mismatch negativity), and receptor‑binding correlates of lasting psychological change following single doses of psilocybin.
Páleníček has been involved in studies that link acute pharmacology to persistent changes in mindfulness, life satisfaction and reductions in psychopathological symptoms, and he has explored 5‑HT2A receptor dynamics as a mechanistic substrate of psilocybin's effects. He also investigates 5‑MeO‑DMT as a pharmacological model for altered or 'deconstructed' conscious states. His work is characterised by translational methods that integrate behavioural, electrophysiological and molecular/neuroimaging measures, and by collaborations within Czech and international psychiatric neuroscience groups focused on advancing the scientific basis for therapeutic applications of psychedelics.
Key Impact
Notable for translational and clinical work on classical and novel serotonergic psychedelics, combining psychopharmacology, neuroimaging and electrophysiology to probe mechanisms underlying altered consciousness and therapeutic effects.
Collaboration Network
60 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Tomáš Páleníček's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Tomáš Páleníček is associated with.